Prognoses of lung adenocarcinoma patients with BMs are often associated with gene mutation status, including mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase-rearranged (ALK), and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (kRAS) [10, 14, 15]. This evidence concerns the gene KRAS and lung adenocarcinoma.